NF1 is a debilitating genetic condition that affects one in every 3,000 to 4,000 individuals. It is caused by a spontaneous or inherited mutation in the NF1 gene and is associated with many symptoms, including soft lumps on and under the skin (cutaneous neurofibromas) and skin pigmentation (so-called ‘café au lait’ spots) and, in 30-50% of patients, tumours develop on the nerve sheaths (plexiform neurofibromas). 

Market Analysis and Insights: Global Neurofibromatosis Type 1 Market
The global Neurofibromatosis Type 1 market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Neurofibromatosis Type 1 Scope and Market Size
The global Neurofibromatosis Type 1 market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neurofibromatosis Type 1 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
10 mg
25 mg

Segment by Application
Hospitals
Clinics
Others

The Neurofibromatosis Type 1 market is analysed and market size information is provided by regions (countries). Segment by Application, the Neurofibromatosis Type 1 market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
AstraZeneca
Merck